# A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)

> **NCT00424476** · PHASE3 · COMPLETED · sponsor: **Human Genome Sciences Inc.** · enrollment: 865 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Placebo
- **DRUG:** Belimumab 1 mg/kg
- **DRUG:** Belimumab 10 mg/kg

## Key facts

- **NCT ID:** NCT00424476
- **Lead sponsor:** Human Genome Sciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2009-05
- **Final completion:** 2010-03
- **Target enrollment:** 865 (ACTUAL)
- **Last updated:** 2016-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00424476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00424476, "A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00424476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*